Intuitive Surgical, Inc. $ISRG Shares Bought by Mogy Joel R Investment Counsel Inc.

Key Points

• Mogy Joel R Investment Counsel Inc. increased its stake in Intuitive Surgical by 1.2%, now holding 68,678 shares valued at approximately $37.32 million.
• Thirteen analysts have rated Intuitive Surgical with a Buy rating, and the average target price for the stock is $595.95.
• Insiders, including EVP Myriam Curet, sold significant amounts of stock recently, with transactions totaling over $21.7 million in the last quarter.

Mogy Joel R Investment Counsel Inc. boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 68,678 shares of the medical equipment provider's stock after buying an additional 840 shares during the quarter. Intuitive Surgical makes up 2.2% of Mogy Joel R Investment Counsel Inc.'s investment portfolio, making the stock its 17th largest holding. Mogy Joel R Investment Counsel Inc.'s holdings in Intuitive Surgical were worth $37,320,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ISRG. Chilton Capital Management LLC grew its stake in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 43 shares during the period. Global Financial Private Client LLC lifted its holdings in Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 38 shares in the last quarter. Elite Financial Inc. purchased a new stake in Intuitive Surgical during the 1st quarter worth about $26,000. LFA Lugano Financial Advisors SA purchased a new stake in Intuitive Surgical during the 1st quarter worth about $30,000. Finally, TD Capital Management LLC lifted its holdings in Intuitive Surgical by 300.0% during the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 45 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

Shares of ISRG stock traded up $2.89 during trading hours on Friday, reaching $438.72. The company had a trading volume of 3,756,410 shares, compared to its average volume of 2,285,360. The stock has a fifty day moving average of $476.64 and a 200-day moving average of $503.68. The company has a market capitalization of $157.27 billion, a price-to-earnings ratio of 61.19, a PEG ratio of 4.60 and a beta of 1.61. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The firm had revenue of $2.44 billion for the quarter, compared to analysts' expectations of $2.35 billion. During the same period in the prior year, the firm posted $1.78 earnings per share. The firm's quarterly revenue was up 21.4% on a year-over-year basis. On average, analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the transaction, the executive vice president directly owned 353 shares in the company, valued at $173,845.44. This represents a 92.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Amy L. Ladd sold 336 shares of the company's stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $470.11, for a total value of $157,956.96. Following the sale, the director owned 1,074 shares in the company, valued at approximately $504,898.14. This trade represents a 23.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,224 shares of company stock worth $21,716,492 over the last ninety days. Corporate insiders own 0.70% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. BTIG Research lifted their price objective on Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Evercore ISI lifted their price objective on Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Piper Sandler restated an "overweight" rating and issued a $595.00 price target (up previously from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. UBS Group lifted their price objective on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $615.00 price target on shares of Intuitive Surgical in a report on Tuesday, August 19th. Thirteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.